
Please try another search
By Davit KirakosyanInvesting.com -- Here is your Pro Recap of the biggest M&A headlines you may have missed on InvestingPro over the past week. Start your free 7-day trial to...
By Davit KirakosyanInvesting.com -- Here is your daily Pro Recap of the biggest dividend headlines you may have missed on InvestingPro. Start your free 7-day trial to get this news...
By Davit Kirakosyan UBS downgraded AppLovin (NASDAQ:APP) to Neutral from Buy and cut its price target to $16.00 from $59.00. While the firm believes AppLovin's software business is...
By Davit Kirakosyan Booking Holdings (NASDAQ:BKNG) reported strong Q4 results, with EPS of $24.74 coming in better than the consensus estimate of $22.00. Revenue grew 36%...
By Davit Kirakosyan Goldman Sachs upgraded NVIDIA (NASDAQ:NVDA) to Buy from Neutral and raised its price target to $275.00 from $162.00, noting that the company delivered...
By Davit Kirakosyan Investing.com -- Here is your daily Pro Recap of the biggest dividend headlines you may have missed on InvestingPro. Start your free 7-day trial to get this...
By Davit Kirakosyan eBay (NASDAQ:EBAY) reported its Q4 results, with EPS of $1.07 coming in better than the consensus estimate of $1.06. Revenue fell 4% year-over-year (down 1% on...
By Davit Kirakosyan Investing.com -- Here is your daily Pro Recap of the biggest dividend headlines you may have missed on InvestingPro. Start your free 7-day trial to get this...
By Davit Kirakosyan Investing.com -- Here is your daily Pro Recap of the biggest earnings headlines you may have missed on InvestingPro since yesterday’s close. Start your...
By Davit Kirakosyan EF Hutton initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy rating and a price target of $304.00. The company announced that the U.S....